Relevant bibliographies by topics / Coronary heart disease – Treatment

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Coronary heart disease – Treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Coronary heart disease – Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Coronary heart disease – Treatment"

1

Nurmamadovna, Ishankulova Nasiba. "Coronary Heart Disease." American Journal of Medical Sciences and Pharmaceutical Research 03, no. 02 (February 28, 2021): 31–36. http://dx.doi.org/10.37547/tajmspr/volume03issue02-04.

Full text
Abstract:
The article covers the etiology, pathogenesis, classification, diagnosis, clinical picture and treatment of coronary heart disease, provides a literature review. Cardiovascular disease (CVD) represents the leading cause of death among women as well as men. The number of deaths due to CVD in women are greater than in men. There are significant gender-related differences concerning CVD.
APA, Harvard, Vancouver, ISO, and other styles
2

Knight, C. J. "Antiplatelet treatment in stable coronary artery disease." Heart 89, no. 10 (October 1, 2003): 1273–78. http://dx.doi.org/10.1136/heart.89.10.1273.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ahmed, Dr Ahmed Mohammed, Abdullah Abdulkhaliq Qazzaz, and Dr Hydair Sachet Khalaf. "Ischemic Heart Disease Treatment." International Journal of Research in Science and Technology 12, no. 01 (2022): 39–41. http://dx.doi.org/10.37648/ijrst.v12i01.005.

Full text
Abstract:
Ischemic heart disease IHD is a rapidly increasing common cause of death in the world. This disease is the insufficient status of oxygen within the cardiac muscles due to an imbalance between oxygen supply and demand, and a cardiac disease that occurs as a result of coronary artery stenosis. Ischemic heart disease diseases are the leading cause of death in both developed and developing countries ,among these IHD is the most prevalent manifestation and is associated with high mortality and morbidity. The clinical presentation of IHD include silent ischaemia, stable angina, unstable angina, myocardial infarction, heart failure and sudden death.
APA, Harvard, Vancouver, ISO, and other styles
4

Clappers, N., M. A. Brouwer, and F. W. A. Verheugt. "Antiplatelet treatment for coronary heart disease." Heart 93, no. 2 (December 30, 2005): 258–65. http://dx.doi.org/10.1136/hrt.2005.071209.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shuper, V. O., S. V. Shuper, I. V. Trefanenko, G. I. Shumko, and T. V. Reva. "Investigation of the Adherence to Prescribed Treatment of the Patients with Coronary Heart Disease." Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 6, no. 5 (October 27, 2021): 263–69. http://dx.doi.org/10.26693/jmbs06.05.263.

Full text
Abstract:
The purpose of the study was to investigate the adherence to secondary prevention medications among patients with coronary heart disease and identify factors associated with it. Materials and methods. We examined 40 patients diagnosed with coronary heart disease of more than 50 years old, who were prescribed with optimal medication for 1 year during hospitalization. Patients` adherence was defined according to MMS-8 Morisky values for secondary prevention medications prescribed by doctors. Also, questionnaires about individual reasons of non-compliance and for individual patient`s opinion about importance and usefulness of knowledge according to risk factors of the increase of cardiovascular mortality were designed and proposed to the patients. Simple descriptive statistics were used to elucidate the characteristics of the patient population and results from individual adherence tools. Final score was analyzed and correlation between patients’ data and level of adherence to prescribed treatment were identified. A correlation matrix (using Spearman’s coefficient) was reviewed for any evidence of collinearity. Results and discussion. Our study demonstrated higher level of non-adherence with secondary prevention medications in patients with coronary heart disease (60.0%). This fact can be explained by the socioeconomic reasons, less informative strategies from the medical staff to the patients. Severe regress of adherence was demonstrated after discharge from the hospital due to subjective improvement of the patients` condition with absence of supervision by out-patient specialists. Demographic characteristics of the patients suggested that some non-modified factors can affect compliance with the prescribed treatment. Better adherence was demonstrated by female married patients with higher educational level, with family history about cardiovascular death. Also, too much prescribed medications with difficult regime of usage with non-adequate out-patient supervision may significantly decrease adherence causing development of complications which may lead to re-hospitalizations and cardiovascular death. Our investigation demonstrated also non-complete information of the patients about lifestyle and medical risk factors of the cardiovascular mortality increase. Conclusion. The results of our study can provide useful practical information on the prevalence and severity of non-adherence among patients with coronary heart disease. Analysis of the factors influencing the adherence demonstrated the main reasons from patients and healthcare professionals affecting the level of compliance with the prescribed treatment. The step towards improving adherence can be initiated by the healthcare professional to overcome the patient's concerns about the prescribed medication. It is important to continue personal monitoring of patients by healthcare professionals in the form of regular inspections of intentional and unintentional non-adherence, including factors and reasons that may change and lead to such behavior
APA, Harvard, Vancouver, ISO, and other styles
6

Korzh, O. M. "CURRENT ASPECTS OF CORONARY HEART DISEASE DIAGNOSIS AND TREATMENT." International Medical Journal, no. 1 (March 5, 2020): 5–10. http://dx.doi.org/10.37436/2308-5274-2020-1-1.

Full text
Abstract:
Among the cardiovascular diseases associated with atherosclerosis, chronic coronary heart disease, including angina, is the most common form. It is the myocardium lesion that develops as a result of an imbalance between the coronary circulation and metabolic needs of heart muscle. The presence of angina symptoms often indicates a pronounced narrowing of one or more coronary arteries, but also occurs in non−obstructive arterial impairment and even in normal coronary arteries. Factors of functional damage to the coronary arteries are spasm, temporary platelet aggregation and intravascular thrombosis. Today there are opportunities not only to use the therapy with proven effectiveness, aimed at reducing the risk of complications, including fatal, but also to treat angina (ischemia), which improves the patient's life quality. The drug protocol includes the ones with a proven positive effect on this disease prognosis, which are mandatory if there are no direct contraindications to use, as well as a large group of antianginal or anti−ischemic drugs. The choice of a particular drug or its combinations with other drugs is carried out in accordance with generally accepted recommendations: taking into account the individual approach, the severity of angina, hemodynamic parameters (heart rate and blood pressure, presence of comorbid conditions). If drug therapy is ineffective, the option of coronary myocardial revascularization (percutaneous coronary angioplasty or coronary artery bypass grafting) is considered. Due to the high mortality and morbidity rates of coronary heart disease worldwide, one of the priorities of practical health care is the prevention of diseases caused by atherosclerosis. Key words: coronary heart disease, angina, family physician, prognosis, drug therapy.
APA, Harvard, Vancouver, ISO, and other styles
7

Cesari, M., G. Rossi, and A. Pessina. "Homocysteine-Lowering Treatment in Coronary Heart Disease." Current Medicinal Chemistry-Cardiovascular & Hematological Agents 3, no. 4 (October 1, 2005): 289–95. http://dx.doi.org/10.2174/156801605774322319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

LaRosa, John C. "Prevention and Treatment of Coronary Heart Disease." Circulation 104, no. 14 (October 2, 2001): 1688–92. http://dx.doi.org/10.1161/hc3901.096665.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Alpert, Joseph S. "Coronary Heart Disease: Prevention, Complications, and Treatment." JAMA: The Journal of the American Medical Association 253, no. 24 (June 28, 1985): 3609. http://dx.doi.org/10.1001/jama.1985.03350480119039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Davidson, Karina W. "Depression and Coronary Heart Disease." ISRN Cardiology 2012 (November 22, 2012): 1–18. http://dx.doi.org/10.5402/2012/743813.

Full text
Abstract:
There are exciting findings in the field of depression and coronary heart disease. Whether diagnosed or simply self-reported, depression continues to mark very high risk for a recurrent acute coronary syndrome or for death in patients with coronary heart disease. Many intriguing mechanisms have been posited to be implicated in the association between depression and heart disease, and randomized controlled trials of depression treatment are beginning to delineate the types of depression management strategies that may benefit the many coronary heart disease patients with depression.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Coronary heart disease – Treatment"

1

Lee, Chi-hang, and 李志恆. "Microvascular obstruction following percutaneous coronary interventionfor coronary artery disease." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43278723.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bose, Jolly. "Percutaneous transluminal coronary angioplasty (PTCA) in the treatment of coronary artery disease in Hong Kong : procedural success, complications and long-term follow-up /." Hong Kong : University of Hong Kong, 1998. http://sunzi.lib.hku.hk/hkuto/record.jsp?B2084282X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Waterhouse, Anna. "Bioengineering a coronary stent with covalently immobilised tropoelastin." Thesis, The University of Sydney, 2011. https://hdl.handle.net/2123/28916.

Full text
Abstract:
This thesis describes the characterisation and development of covalently immobilised recombinant human tropoelastin (TE) on a plasma-activated coating (PAC) as a potential stent coating for the treatment of coronary artery disease. A biomimetic approach was used to create a biocompatible coating with an immobilised human protein to enhance biointegration of an implanted stent. A coating that enhanced endothelialisation while displaying low tbrombogenicity was developed and characterised in vitro and in vivo. Covalent binding of TE to PAC was verified using ELISA and radiolabelled TE. Modulating the gas composition of the PAC, and therefore its mechanical and biological properties, resulted in varying amounts of covalently bound TE. The nitrogen containing PA Cs covalently bound up to 89± 1 % of physisorbed TE. The N2/Ar PAC covalently bound a monolayer of TE and was chosen for further characterisation. The covalent binding capacity of PAC extended for at least a year, retaining 65±1 % of its covalent TE binding capacity. Restoration of the full covalent binding capacity was achieved upon heat treatment of the PAC. TE was shown to support the attachment and proliferation of endothelial cells (ECs) when physisorbed to tissue culture plastic (TCP). This was comparable to other adhesive extracellular matrix proteins, fibronectin and collagen. The morphology and distribution of ECs cultured on 316L SS, PAC and PAC+TE was investigated using reflective, fluorescence and scanning electron microscopy. PAC+TE supported increased endothelial attachment and proliferation compared to uncoated 3 l 6L SS and PAC. An EC phenotype was confirmed on 316L SS, PAC and PAC+TE by immunofluorescent labelling of endothelial cell specific markers, CD3 I and vWF. As the thrombogenicity of blood contacting medical devices is crucial, methodology was developed to test the haemocompatibility of metallic surfaces in vitro. In static adhesion assays using whole heparinised blood, PAC was found to confer low thrombogenicity compared to 3 l 6L SS, and nitrogen again modulated this property. PAC and PAC+TE showed lower thrombogenicity than 316L SS after 60 min incubation. A modified Chandler loop was developed to test the tbrombogenicity of metallic surfaces in the presence of flowing blood. PAC and PAC+TE were again found to display low thrombogenicity, resulting in a 3-fold increase in the time to thrombus formation compared to 3 I 6L SS. This effect correlated with a 65±1 % increase in soluble P-selectin, a platelet activation marker on 3 l 6L SS. No significant platelet activation occurred on PAC or PAC+TE. The low thrombogenicity of PAC was retained for between 3 and 7 months. Furthermore, TE coated 3 I 6L SS displayed lower thrombogenicity than uncoated 316L SS, or fibronectin-or collagen-coated 316L SS. The PAC was translated to a 316L SS laser cut stent for evaluation and in vivo testing. The PAC deposition was altered to coat all surfaces and resisted delamination. In vitro crimping and expansion of the PAC stent showed only the formation of nanocracks, compared to the large scale delamination observed on a commercially available Taxus Liberte stent. The covalent TE binding capacity and non-thrombogenicity of the PAC were maintained on the stent PAC. The endothelialisation of PAC and PAC+TE stents was evaluated in vivo. This study marks the first comparator analysis of bare metal stents (BMS), PAC and PAC+ TE stents in a well-characterised model of rabbit bilateral iliac stenting. PAC and PAC+ TE stents were well tolerated and showed no gross inflammatory response. Cell coverage of stent struts occurred by 7 days post-implantation with endotheJialisation occurring both between the struts and over the struts in all samples. PAC and PAC+ TE showed no difference in the rate of endothelialisation compared to BMS, the standard corrunerciaJly available stents. In further work, covalently immobilised TE was found to be susceptible to proteolytic cleavage by the common blood plasma proteases kallikrein and thrombin, which predominantly cleave TE at its arginine 515 residue. A mutant form of TE, R5 I 5A was shown to resist proteolytic cleavage at the 515 residue and thus retained the C-terminus of the protein which is required for cell attachment. This mutant form of TE retained the equivalent level of covalent binding to PAC and would therefore be a suitable candidate for application to a PAC stent for in vivo evaluation.
APA, Harvard, Vancouver, ISO, and other styles
4

Kärner, Anita. "Patients' and spouses' perspectives on coronary heart disease and its treatment /." Linköping : Univ, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-5264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kärner, Anita. "Patients’ and Spouses’ Perspectives on Coronary Heart Disease and its Treatment." Doctoral thesis, Linköpings universitet, Hälsa, Aktivitet, Vård (HAV), 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-5264.

Full text
Abstract:
Background: Lifestyle changes and drug treatment can improve the prognosis and quality of life for patients with coronary heart disease (CHD), but their co-operation with suggested treatment is often limited. The aim of this thesis was to study how patients and their spouses conceive CHD and its treatment. Material and Methods: The research design used was inductive and descriptive. The studies were based on three complementary sets of data. Patients with CHD (n=23) and spouses (n=25) were interviewed one year after an episode of the disease. Consecutive patients with CHD derived from another investigation were interviewed within six weeks or one year after the coronary event (n=113). All semi-structured interviews, tape-recorded or from notes taken by hand, were subjected to analysis within the phenomenographic framework. Findings: The patients’ conceptions of CHD varied and were vague, even as judged on a lay level. They were associated with symptoms rather than with the disease. Co-operation with drug treatment was rarely linked to improved prognosis. The patients’ descriptions of benefits from lifestyle changes and treatment did not give the impression of being based on a solid understanding of the importance of such changes. Incentives for lifestyle changes were classified into four categories, all of which contained both facilitating and constraining incentives. Somatic incentives featured direct and indirect physical signals. Social/practical incentives involved shared concerns, changed conditions, and factors connected with external environment. Cognitive incentives were characterised by active decisions and appropriated knowledge, but also by passive compliance with limited insights, and by the creating of routines. Affective incentives comprised fear and reluctance related to lifestyle changes and disease and also lessened self-esteem. All incentives mostly functioned facilitatively. The cognitive and the social/practical incentives were the most prevalent. Spouses’ understanding about the causes of CHD involved both appropriate conceptions and misconceptions. Drug treatment was considered necessary for the heart, but harmful to other organs. Spouses’ support to partners was categorised, and found to be contextually bound. The participative role was co-operative and empathetic. The regulative role controlled and demanded certain behaviours. The observational role was passive, compliant, and empathetic. The incapacitated role was empathetic, unable to support, and positive to changes. The dissociative role was negative to changes and reluctant to be involved in lifestyle changes. Conclusions: These results could be useful in the planning of care and education for CHD patients. The findings also emphasise the importance of adopting a family perspective to meet the complex needs of these patients and their spouses in order to facilitate appropriate lifestyle changes.
On the day of the public defence of the doctoral thesis the status of article V was Submitted.
APA, Harvard, Vancouver, ISO, and other styles
6

Baird, Simon Herbert. "Progress in diagnosis and treatment of acute coronary syndromes." Thesis, Queen's University Belfast, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.326416.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ko, Weng-wah Wendy. "Morphine treatment and acute myocardial ischaemia in rats /." [Hong Kong] : University of Hong Kong, 1988. http://sunzi.lib.hku.hk/hkuto/record.jsp?B12358745.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dall'Armellina, Erica. "Applications of 3T CMR in acute coronary syndromes (ACS)." Thesis, University of Oxford, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.589619.

Full text
Abstract:
Introduction There is a pressing clinical need to treat patients with acute coronary syndrome (ACS) timely and efficiently in order to improve their prognosis. Standard tools available in ED, while useful, do not comprehensively characterize ACS for either diagnosis or risk stratification. The role of CMR in ACS is emerging because it allows assessment of both myocardial composition and function. Newer CMR techniques such as: a) T2 W imaging for assessing myocardial oedema and area at risk B) pre contrast T1 mapping techniques for quantitative characterization of the tissue composition, are adding further utility for CMR in ACS. At present the clinical use of these techniques is still limited and further investigations are needed to assess their clinical applicability in ACS patients. Aims The aims of this thesis were several. Firstly we sought to establish a CMR protocol for imaging ACS patients on a 3T CMR scanner. In order to do so, we validated a novel T2 W technique for oedema imaging (T2 prep SSFP) at 3T. Second, we aimed to perform a detailed study of the time course of oedema in ACS patients in order to establish the appropriate imaging time for the assessment of area at risk. Third, by applying T2W acute oedema imaging, we sought to investigate the functional and pathological meaning of complicated remote plaques in patients with multivessel disease. Finally, we aimed to establish whether, in comparison to standard CMR techniques, novel precontrast Tl mapping allows better characterisation of the acutely injured myocardium and whether it can predict long-term functional recovery. Methods The research studies were all performed on a 3T Trio Siemens scanner. In the initial stage of the research, we validated the T2 W technique performing phantom work and scanning both volunteers and patients to assess the uniformity of signal intensity in the myocardium and to establish a threshold based method to post process the images. We then established a CMR protocol for ACS including oedema imaging, T1 mapping imaging, perfusion, functional and late gadolinium enhancement imaging. Patients with acute myocardial infarction (both ST elevation myocardial infarction (STEMI) and non STEMI) were scanned at 4 different time points after the acute event (3 scans within 2 weeks and one at 6 months). All STEMI patients underwent primary percutaneous coronary intervention (PCI) while the non-STEMI patients underwent coronary angiography and for PCI. Results We validated the T2prep SSFP technique at 3T, highlighting its limitations and establishing a threshold of mean ± 2SD to assess myocardial oedema. We found that the optimal imaging window to assess the maximal expression of myocardial oedema was within 1 week from the acute event in patients with ST elevation MI. Also, our results showed a reduction of LGE over time (from acute to chronic) in segments which also showed improvement in contractile function indicating that even segments with transmural LGE assessed in the early hours post event could be viable. By applying these techniques in acute patients with bystander disease undergoing percutaneous coronary intervention, we found that: l) T2W imaging can detect myocardial injury downstream from a vessel identified as "non culprit" 2) in 20% of NSTEMI patients, the angiographic assessment alone failed to identify the culprit vessel. Finally, we found that the diagnostic performance of acute pre-contrast Tl-mapping was at least as good as that ofT2W CMR for detecting myocardial injury. There was a significant relationship between the segmental damaged fraction assessed by either by LGE or T2W, and mean segmental Tl values and the likelihood of improvement of segmental function at 6 months decreased progressively as acute Tl values increased. Conclusions In summary, we defined a stable imaging window for the retrospective evaluation of area at risk and we also indicated that acutely detected LGE does not necessarily equate with irreversible injury and may severely underestimate salvaged myocardium. Furthermore, in NSTEMI patients with multivessel disease, by revealing acute myocardial damage in territories pertaining to vessels not treated acutely, we raised the issue of the need for better tools for the correct identification of the culprit vessel and to stratify patients rather than by angiographic assessment alone. Finally, we demonstrated how pre-contrast Tl mapping allows for assessment of the extent of myocardial damage and how Tl mapping might become an important complementary technique to LGE and T2W for the identification of reversible myocardial injury and the prediction of functional recovery in acute MI.
APA, Harvard, Vancouver, ISO, and other styles
9

Lalonde, Lyne. "Health-related quality of life measures in coronary heart disease prevention and treatment." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0006/NQ44484.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lincoln, White Simon Jonathan. "Cardiac rehabilitation patients' perspectives on coronary heart disease and treatment : a qualitative study." Thesis, University of Nottingham, 2008. http://eprints.nottingham.ac.uk/10608/.

Full text
Abstract:
UK hospital-based Cardiac Rehabilitation (CR) programmes offer eligible Coronary Heart Disease (CHD) patients information on various issues including lifestyle modification and medicines. However, CR patients' perspectives on medicine-taking and lifestyle modification in relation to their perspectives on their risk of experiencing further CHD-related events remains under-researched. This study explored these topics. Following ethical approval, a qualitative approach was taken that drew on the broad principles of grounded theory. In-depth, audiotaped interviews were conducted with sixteen CR patients approximately three months after hospital discharge. Second interviews explored whether heart attack CR patients' perspectives on risk, medicines and lifestyle modification had changed when interviewed again approximately nine months later. The perspectives of a group of CR patients who had not had a heart attack were explored for comparison. Findings suggested that CR patients made sophisticated yet uncertain assessments of their risk. This did not just involve identifying lifestyle factors needing change or attributing the likelihood of experiencing further CHD-related events to chance or heredity alone; patients tended to also consider information about heart damage or current heart function. Heart attack patients commonly feared recurrence, which appeared to heighten short-term perceptions of risk but longer-term perspectives on risk appeared similar to CR patients who had not had a heart attack. CR patients tended to only maintain changes to aspects of lifestyle perceived as causes, rather than viewing lifestyle recommendations as standards to achieve. Some heart attack patients initially changed aspects of lifestyle they did not cite as a cause, which seemed to be associated with heightened risk perceptions, since these changes tended not to be maintained. CR patients reported continuing to take heart-related medicines and viewed them as important to reduce their risk, despite disquiet about medicines causing harm being common. These findings have implications for health professionals' practice and CR programme improvement.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Coronary heart disease – Treatment"

1

1935-, Walter P. J., ed. Treatment of end-stage coronary artery disease. Basel: Karger, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1951-, Hasselbring Bobbie, ed. Coronary heart disease: A guide to diagnosis and treatment. Omaha, Neb: Addicus Books, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

W, Serruys P., and Kutryk Michael J. B, eds. Handbook of coronary stents. 3rd ed. London: Martin Dunitz, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Guan xin bing zhong xi yi shuang xiao zi liao shou ce. Taibei shi: Wang wen she gu fen you xian gong si, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Du, Tongfang. Guan xin bing Zhong Xi yi zhen liao yu tiao yang =: Coronary artery disease. Xianggang: Tian heng wen hua chu ban gong si, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Guan xin bing Zhong xi yi shuang xiao zi liao shou ce. Xianggang: San lian shu dian (Xianggang) you xian gong si, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cohen, Barry M. Coronary heart disease: A guide to diagnosis and treatment. 2nd ed. Omaha, Neb: Addicus Books, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Foundation, Irish Heart. Heart attack and life style. Dublin: Irish Heart Foundation, Foras Croí na hÉireann, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mathur, Sushma. Epidemic of coronary heart disease and its treatment in Australia. Canberra: Australian Institute of Health and Welfare, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

L, Wilensky Robert, ed. Unstable coronary artery syndromes: Pathophysiology, diagnosis, and treatment. Boston: Kluwer Academic Publishers, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Coronary heart disease – Treatment"

1

Wilson, Robert F. "Transcatheter Treatment of Coronary Artery Disease." In Coronary Heart Disease, 389–403. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-1475-9_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Liao, Kenneth. "Surgical Treatment of Coronary Artery Disease." In Coronary Heart Disease, 405–22. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-1475-9_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bogaev, Roberta C., and Deborah E. Meyers. "Medical Treatment of Heart Failure and Coronary Heart Disease." In Coronary Artery Disease, 533–60. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-2828-1_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mallidi, Hari R., William E. Cohn, and O. H. Frazier. "Surgical Treatment of Advanced Heart Failure." In Coronary Artery Disease, 561–79. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-2828-1_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brouwer, René M. H. J., Maarten P. van den Berg, and Eduard L. Mooyaard. "Surgical Treatment of Heart Failure." In Advanced Imaging In Coronary Artery Disease, 321–33. Dordrecht: Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-007-0866-2_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Laham, Roger J. "Percutaneous Treatment of Coronary Artery Disease." In Device Therapy in Heart Failure, 263–86. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-424-7_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chong, Aun-Yeong, Terry Meadows, and David Glineur. "Complex Coronary Revascularization Heart Team." In Heart Teams for Treatment of Cardiovascular Disease, 11–22. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-19124-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lorimer, A. Ross, and W. Stewart Hillis. "Indications for Surgery in Coronary Heart Disease." In Treatment in Clinical Medicine, 119–24. London: Springer London, 1985. http://dx.doi.org/10.1007/978-1-4471-3120-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kop, W. J., and D. N. Ader. "Depression in Coronary Artery Disease: Assessment and Treatment." In Clinical Psychology and Heart Disease, 109–19. Milano: Springer Milan, 2006. http://dx.doi.org/10.1007/978-88-470-0378-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Heusch, Gerd, and B. D. Guth. "New aspects on the pathophysiology of coronary heart disease." In Treatment with Gallopamil, 65–84. Heidelberg: Steinkopff, 1989. http://dx.doi.org/10.1007/978-3-642-85376-0_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Coronary heart disease – Treatment"

1

Zhu, Huizheng. "Strategies for Early Diagnosis and Treatment of Coronary Heart Disease." In 2016 International Conference on Economy, Management and Education Technology. Paris, France: Atlantis Press, 2016. http://dx.doi.org/10.2991/icemet-16.2016.286.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Advances in Antithrombotic Treatment of Coronary Heart Disease Complicated with Atrial Fibrillation." In 2018 International Conference on Medicine, Biology, Materials and Manufacturing. Francis Academic Press, 2018. http://dx.doi.org/10.25236/icmbmm.2018.69.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bian, Yanqin, Kai Cui, Lingru Wang, Guang Zheng, Hongtao Guo, Jing Yang, Miao Jiang, and Aiping Lu. "Application of acupuncture on coronary heart disease treatment: A text mining study." In 2014 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2014. http://dx.doi.org/10.1109/bibm.2014.6999311.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Meng, Lingdong, and Yuntao Cheng. "Analysis on the Treatment of Trimetazidine Jointed with Metoprolol in the Coronary Heart Disease with the Heart Failure." In 2015 International Forum on Bioinformatics and Medical Engineering. Paris, France: Atlantis Press, 2015. http://dx.doi.org/10.2991/bme-15.2015.9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Jenny, Jessica S. Coogan, Hyun Jin Kim, and Charles A. Taylor. "Pressure and Flow Characterization for Different Idealized Models of Stenotic Coronary Arteries." In ASME 2010 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2010. http://dx.doi.org/10.1115/sbc2010-19329.

Full text
Abstract:
Coronary artery disease is one of the leading causes of death worldwide. This year, an estimated 785,000 Americans will have a new coronary attack [1]. Treatment of coronary artery disease varies from medication alone to cardiovascular surgery. Treatment regimens depend on the number and hemodynamic significance of stenoses present. In this study, we created idealized models of stenotic coronary arteries with varying geometric properties and simulated flow and pressure in coronary stenoses using a novel computational method including a three-dimensional model of an idealized coronary artery coupled to a lumped parameter model of the heart at the inlet and a lumped parameter model of the distal coronary vasculature at the outlet.
APA, Harvard, Vancouver, ISO, and other styles
6

Reshetov, Aleksey, German Nikolaev, Aleksey Elkin, Sergey Snepanov, Dmitriy Ermakov, and Vasiliy Klimenko. "Two-stage treatment of non-small cell lung cancer (NSCLC) in patients with severe coronary heart disease." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4662.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sandset, P. M., P. A. Sirnes, U. Abildgaard, and M. Petterson. "PREACTIVATION AND INHIBITION OF EXTRINSIC COAGULATION PATHWAY IN ACUTE CORONARY DISEASE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643024.

Full text
Abstract:
It has recently been shown that plasma from individuals with a high risk score for developing AMI shows an abnormal depression of factor VII (EVII) coagulant activity after treatment with phospholipase C (PLC), (Dalaker, K.& Prydz, H., Br . J . Haematol. 61,315, 1985) revealing the presence of “preactivated” FVII in complex with lipid. We have studied this phenomenon in patients in a coronary unit, by serial determinations of Normotest (NT) + PLC pretreatment (which correlates with FVII clotting) assay ± PLC) and EVII amidolytic assay (EVIIram) (OswaldsBn et al., Tromb.Haemostas. 54,26,1985). The newly described inhibitor of FVII-Tissue thromboplastin (EPI) was also measured. Mean patient values day 2 are listed:More than 20% depression of NT by PLC treatment was found in 2/14 controls, 9/19 AMI patients, 3/17 angina patients and 2/15 patients with other heart disease. The EVII:am values correlated better with NT (r = 0.81) than with PLC+NT (r=0.62). It has been suggested that FVII:am correlates with the molar concentration of FVII. If correct, our data precludes two chain FVII as contributing much to preactivation. EPI values were in the high normal range for all three groups of heart patients. The individual variation in EPI values was great, particularly in AMI patients. Apparently, EPI did not correlate to any of the FVII assays. Three patients with more then 50% reduced NT after PLC had EPI values 67, 149, and 130%. In conclusion, lipid activation was frequent in AMI patients, and was not related to EPI activity.
APA, Harvard, Vancouver, ISO, and other styles
8

Ivanov, Zhanna A., Robert C. Scott, Jenna Rosano, Barbara Krynska, and Mohammad F. Kiani. "Engineering Cardiac Tissue Using Stem Cell Therapy to Mend the Broken Heart." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-203624.

Full text
Abstract:
Myocardial infarction (MI) is one of the most severe forms of coronary artery disease and is the leading cause of death in the United States [1]. Current treatments for an MI are either highly invasive, such as coronary artery bypass grafting and stent angioplasty, or might have undesirable long-term effects as is the case with pharmacological interventions. However, newly emerging methodologies, such as a less invasive stem cell therapy, aim to cure the disease rather than just alleviate its symptoms. This new tissue engineering technology has shown promise in restoring the homeostasis of the heart muscle after MI in preclinical and clinical studies [2]. However, controversies regarding inconsistent methodologies and a lack of mechanistic understanding of its actions have hampered progress in this field [3].
APA, Harvard, Vancouver, ISO, and other styles
9

Sengupta, Dibyendu, Jane C. Burns, Andrew Kahn, and Alison L. Marsden. "Patient-Specific Hemodynamic Simulations in Coronary Artery Aneurysms Caused by Kawasaki Disease." In ASME 2010 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2010. http://dx.doi.org/10.1115/sbc2010-19591.

Full text
Abstract:
Kawasaki disease (KD) is an acute pediatric illness and the leading cause of acquired heart disease in children, with over 4,000 cases diagnosed annually in the US. The incidence of KD in San Diego County is 25/100,000 for children less than 5 years of age. In absence of a diagnostic test for KD, many patients are not diagnosed in time to receive treatment with intravenous gamma globulin. Approximately 25% of untreated patients develop large aneurysms in their coronary arteries, which puts them at risk for myocardial infarction. In this project we performed patient specific computational simulations of blood flow in aneurysmal left and right coronary arteries of a 10-year-old KD patient. Several relevant hemodynamic parameters such as wall shear stress (WSS) and recirculation time were obtained, as a first step toward developing a risk assessment tool for thrombosis in KD patients.
APA, Harvard, Vancouver, ISO, and other styles
10

Mesihović-Dinarević, Senka. "WHAT IS NEW IN CARDIOVASCULAR MEDICINE?" In Symposium with International Participation HEART AND … Akademija nauka i umjetnosti Bosne i Hercegovine, 2019. http://dx.doi.org/10.5644/pi2019.181.03.

Full text
Abstract:
The rapid pace of change continues to be a hallmark in cardiovascular medicine and many see that pace accelerating in adult cardiovascular medicine as well as in paediatric cardiology medicine. Cardiovascular medicine is an area of clinical practice with a continually rapid expansion of knowledge, guidelines, best practices and new technology. Cardiovascular diseases are the leading cause of mortality in the world and cause major costs for the health sector and economy. Primary care clinicians are challenged to optimally manage a multitude of diseases including congestive heart failure, coronary artery disease, valvular diseases, arrhythmias, lipid disorders, and hypertension. Multimodality imaging techniques are being used more frequently as their utility is better appreciated. Echocardiography has been the mainstay approach, cardiac computerized tomography and magnetic resonance imaging provide a good imaging alternative for patients with multiple complex surgeries. 3D printing has seen a rapid growth in use for planning treatments for patients with congenital heart disease. Simulation using 3D models is emerging as a fundamental resource for teaching procedural techniques and a new standard of care. Artificial intelligence holds the greatest potential for revolutionizing medicine. Innovative technologies in the world of cardiovascular health are expanding every day: wearable computing technologies, bioresorbable stents, leadless pacemaker, valve-in-valve procedure, protein patch for heart muscle growth and others. As a part of lifelong learning process for all professionals in cardiovascular medicine, the imperative is to have continuity of reviewing novelties, with results data from numerous researches in order to treat patient according to best practices and evidence-based medicine.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Coronary heart disease – Treatment"

1

Wang, Shuang, Aidong Liu, Zhilei Wang, and Yue Zhang. Efficacy and safety of acupuncture combined with Chinese herbal medicine in the treatment of angina pectoris of coronary heart disease: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0100.

Full text
Abstract:
Review question / Objective: This study is the protocol for a systematic review to evaluate the Efficacy and safety of acupuncture combined with Chinese herbal medicine in the treatment of angina pectoris of coronary heart disease: a systematic review and meta-analysis. we conducted a systematic review and meta-analysis of published randomized clinical trials (RCTs) of such combined therapy in the treatment of angina pectoris of coronary heart disease, It provides a reliable scientific basis for clinicians to use this approach to treat angina pectoris of coronary heart disease. Information sources: We conducted a systematic search for relevant documents in the Chinese and English databases, and the search time is limited to November 23, 2021. The following eight databases are included : PubMed,EMBASE, Web of Science, The Cochrane Library, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), Wanfang Database.Relevant journals were searched to trace the references included in the study. Other resources will be searched if necessary.
APA, Harvard, Vancouver, ISO, and other styles
2

Weng, JIeqiong, Jingfang Zhang, Ke Xu, Mengfei Yuan, Tingting Yao, Xinyu Wang, and Xiaoxu Shen. Efficacy of Shexiang Baoxin Pills Combined with Statins on Blood Lipid Profile in Patients with Coronary Heart Disease: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0100.

Full text
Abstract:
Review question / Objective: P（Population) ：Patients with coronary heart disease; I（Intervention) : Statins treatment in combination with Shexiang Baoxin pill; C（Comparison): Statins alone; O（Outcome）: Improvement of symptoms and blood lipids; S（Study design）：Clinical randomized trials. Eligibility criteria: To be included, trials were required to meet the following criteria: (1) patients were included in the studies according to diagnostic criteria of coronary heart disease established by the WHO, InternationalSociety of Cardiology and Association (ISCA), Internal Medicine, 7th edition ( IM-7th), Practice of InternalMedicine, 14th edition ( PIM-14th), Guidelines for the Diagnosis of Cardiovascular Diseases in InternalMedicine, 3rd edition (GIM-3rd) or conventional diagnostic criteria (CDC) including assessment of anginapectoris and electrocardiogram (ECG) results; (2) the study was conducted as a randomized controlled trial.
APA, Harvard, Vancouver, ISO, and other styles
3

Pan, JianLue, Pangning Huang, Yuanwen Zhang, RongFa Huang, QiuCen Chen, and HuiBing Chen. Commonly Traditional Chinese Medicine in treatment of Coronary Atherosclerotic Heart Disease with Anxiety and Depression: a network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2021. http://dx.doi.org/10.37766/inplasy2021.4.0124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Yali, Yong Liu, Ziqu Zhang, and Yuyun Zhai. Effect of anti-helicobacter pylori treatment on coronary atherosclerotic heart disease: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0125.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fan, Maoxia, Ying Tian, and Dong Guo. Efficacy and safety of Xinkeshu in the treatment of angina pectoris of coronary heart disease: A systematic review and meta-analysis protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhang, Xiaoyu, Yingwei Wang, Lufei Liu, Hui Jiang, Jing Wang, Yang Xiao, and Jianwei Wang. Efficacy of Wen-Dan Decoction in the treatment of patients with coronary heart disease: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

LI, Peng, and Junjun Liu. Effect of statin therapy on moderate-to-severe depression: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0016.

Full text
Abstract:
Review question / Objective: We aim to assess the antidepressant effects of statin therapy among patients complicated with moderate to severe depression. Condition being studied: Depression is one of the major causes of disability worldwide, and major depressive disorders (MDD) contribute to a significant heavy disease burden, which is expected to be second by 2050, only to heart disease. Despite great improvement in therapy, the treatment efficacy remains low. Therefore, alternative therapies have been intensely investigated. A substantial body of researches have suggested that inflammation is one of the operative pathways between MDD and increased risk of somatic comorbidities, and some specific depressive symptoms. Depression occurs in most patients with cardiac and cerebrovascular disease due to the long-term effects, and depression increases the risk of cardiovascular disease in the population as a whole and in patients with coronary artery disease or stroke. Several observational studies have demonstrated reduced rates of depression among patients taking statins, which may be related to its anti-inflammatory effect. However, whether statin improves the depressive symptoms and its associated mechanism is still mixed. Furthermore, there is little evidence about statin treatment effect in those with moderate to severe depression. In addition, whether the effect of statin treatment on depressive symptom changes with time or is affected by baseline depression severity or percentage change of lipid levels has not been explored in previous studies.
APA, Harvard, Vancouver, ISO, and other styles
8

Dong, Guoqi, Mengye Lu, Xiaoliang Wu, Hao Chen, Hongru Zhang, and Yihuang Gu. Network meta-analysis of Traditional Chinese medicines for depression in coronary heart disease patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wienke, Andreas, Anne M. Herskind, Kaare Christensen, Axel Skytthe, and Anatoli I. Yashin. The influence of smoking and BMI on heritability in susceptibility to coronary heart disease. Rostock: Max Planck Institute for Demographic Research, January 2002. http://dx.doi.org/10.4054/mpidr-wp-2002-003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cai, Ruping, Yuli Xu, and Qiang Su. Meta-analysis of blood lipid reduction for patients with coronary heart disease by combination of pitavastatin and ezetimibe. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0072.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Coronary heart disease – Treatment' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography